Lisata Therapeutics, Inc. (LSTA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 52/100 (HIGH), 5.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.55% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Lisata adds biopharma finance veteran Jeffrey Farrow to board
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Lisata Therapeutics wins new US patent for pancreatic cancer drug
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
- Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
- MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher
- Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Lisata Therapeutics, Inc..
Full LSTA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.